ClinicalTrials.gg
RecruitingNCT06576713ParkOmicUpdated Aug 21, 2026

Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism

An interventional study of Combiner whole genome and RNA sequencing in Parkinson's Disease, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.

Planned enrollment
293rd of 328
14 · median 64
Started
2025
with 16 others
No phase
179 of 428
36 open now
Primary completion
2027-01
later than 34 of 75 live
Registered
394th of 428
by date

Among the 428 studies in Parkinson Disease with a site in France, this one is the 293rd largest by planned enrollment of the 328 interventional ones that give a count, is one of 17 that started in 2025, is one of 179 with no phase, reaches primary completion later than 34 of the 75 other live ones, and was the 394th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 428 studies in Parkinson Disease with a site in France, or all of them as a file.
02

Study summary

Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.

Studying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.

In this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.

Read the detailed description

Investigators selected 14 patients with early-onset parkinsonism for whom no variant of certain pathogenicity had been identified after exome sequencing.

Patients and their relatives will have a blood sample collection following the inclusion visit for DNA extraction, patients will receive a skin biopsy for fibroblast culture and RNA extraction for RNA sequencing. The genome sequencing will be performed on an Illumina® HiSeq4000 sequencer.

Investigators will also perform skin biopsies on patients for fibroblast cultures in order to extract RNA for RNA sequencing. The choice of fibroblast analysis for the study of the transcriptome is justified by the fact that genes expressed in the brain likely to be associated with neurodegenerative diseases are more frequently expressed in the skin than in the other clinically accessible tissues such as blood. Skin biopsies will be performed by the referring clinicians, and RNA extraction will be carried out using the Quiagen® RNeasy kit.

Transcriptome analysis by RNA sequencing including sequencing and bioinformatics processing of data, including detection of aberrant splicing (LeafCutter), aberrant expressions (DESeq) and identification of variants (GATK + Varank) will also be carried out Genome data will be integrated with data from RNA sequencing. Investigators plan to analyze all 14 patients according to this strategy.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Extrapyramidal syndrome beginning before or at the age of 40 or associated with a family history:
  • Dopaminergic denervation proven by ioflupane brain scintigraphy (DaTscan®)
  • DNAs from both asymptomatic parents available in biobank
  • Subject affiliated to a social protection health insurance scheme or beneficiary or beneficiary
  • Subject able to understand the objectives and risks related to the research and to give dated and signed

Exclusion criteria

Exclusion Criteria:

  • - for performing a superficial skin provided for by the protocol
  • Molecular cause of parkinsonism previously identified
  • Absence of prior genetic exploration by high-throughput DNA sequencing
  • Patient with late-onset sporadic parkinsonian syndrome (> 40 years) without family history
  • Patient with Parkinson's syndrome associated with a specific diagnosis (genetic or non-genetic pathology: exposure to neuroleptics, toxic origin)
  • Impossibility of providing the subject with informed information
  • Subject under judicial protection
  • Subject under guardianship or curatorship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Genome and RNA sequencing

    Diagnostic Test: Combiner whole genome and RNA sequencing

Interventions

  • Diagnostic testCombiner whole genome and RNA sequencing

    High-throughput DNA and RNA sequencing

06

What researchers measure

Primary outcomes

  1. Genetic diagnosis rate

    To estimate the rate of genetic diagnoses obtained by genome sequencing coupled with RNA sequencing within a cohort of patients presenting with early onset or familial parkinsonian syndromes without molecular diagnosis.

    Time frame: 18 months

Secondary outcomes

  1. Genes implicated

    Estimate the proportion of patients carrying pathogenic or probably pathogenic variants in each of the genes identified in this work

    Time frame: 18 months

  2. Contribution of RNA sequencing

    Estimate the proportion of pathogenic or probably pathogenic variants detected secondarily thanks to the contribution of RNA sequencing and not identified by analysis of the genome taken in isolation.

    Time frame: 18 months

  3. Genotype and Phenotype correlation

    Estimate the proportion of patients presenting specific clinical, biological and imaging characteristics for each identified genetic cause (genotype/phenotype correlation).

    Time frame: 18 months

  4. New genetic causes

    Describe new molecular mechanisms of parkinsonian syndromes.

    Time frame: 18 months

  5. Tolerance

    Estimate the proportion of patients experiencing an adverse event related to the procedure.

    Time frame: 18 months

  6. New associated genes

    Describe new genes associated with parkinsonian syndromes.

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 23 months is close to that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 29, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06576713
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Jan 14, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

THOMAS WIRTH
Contact
thomas.wirth@chru-strasbourg.fr
03.88.12.80.19 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion